Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials

Haematologica

Volumn 98, Issue 6, 2013, Pages 980-987

  Bringhen, Sara ^a   Mateos, Maria Victoria ^b   Zweegman, Sonja ^c   Larocca, Alessandra ^a   Falcone, Antonietta Pia ^d   Oriol, Albert ^e   Rossi, Davide ^f   Cavalli, Maide ^g   Wijermans, Pierre ^h   Ria, Roberto ⁱ   Offidani, Massimo ^j   Lahuerta, Juan Jose ^k   Liberati, Anna Marina ^l   Mina, Roberto ^a   Callea, Vincenzo ^m   Schaafsma, Martijn ⁿ   Cerrato, Chiara ^a   Marasca, Roberto ^o   Franceschini, Luca ^p   Evangelista, Andrea ^q   Teruel, Ana Isabel ^r   van der Holt, Bronno ^s   Montefusco, Vittorio ^t   Ciccone, Giovannino ^q   Boccadoro, Mario ^a   Miguel, Jesus San ^b   Sonneveld, Pieter ^s   Palumbo, Antonio ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b CSIC   (Spain)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h HAGA HOSPITAL   (Netherlands)

ⁱ UNIVERSITY OF BARI   (Italy)

^j OSPEDALI RIUNITI   (Italy)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^l UNIVERSITY OF PERUGIA   (Italy)

^m Azienda Ospedaliera   (Italy)

ⁿ MEDISCH SPECTRUM TWENTE   (Netherlands)

^o UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^p TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^q AOU San Giovannni Battista e CPO Piemonte   (Italy)

^r HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^s ERASMUS MEDICAL CENTER   (Netherlands)

^t NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; MELPHALAN; PREDNISONE; THALIDOMIDE;

AGED; ANEMIA; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; DISEASE COURSE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SECOND CANCER; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84878468191     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.075051     Document Type: Article

References (46)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER website 2010.
2. Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med. 2011;364(11):1046-60.
3. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-18.
4. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22):3664-70.
5. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367(9513):825-31.
6. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008:112(8):3107-14.
7. Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28(19):3160-6.
8. Waage A, Gimsing P, Fayers P, Ammerlaan R, Wittebol S, Sinnige H, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116(9):1405-12.
9. Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H, Aydogdu I, Konuk N, et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2010;86(1):16-22.
10. Fayers PM, Palumbo A, Hulin C, Ozdogu H, Aydogdu I, Konuk N, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118(5):1239-47.
11. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-17.
12. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259-66.
13. Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934-41.
14. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalanprednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101-9.
15. Katsahian S, Resche-Rigon M, Chevret S, Porcher R. Analysing multicentre competing risk data with mixed proportional hazards model for the subdistribution. Stat Med. 2006;25(24):4267-78.
16. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93(1):51-4.
17. Lenhoff S, Hjorth M, Westin J, Brinch L, Bäckström B, Carlson K, et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol. 2006;133(4):389-96.
18. Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 1999;13 (2):79-90.
19. Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma. 2009;9(4):302-6.
20. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109(6):2604-6.
21. Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007;92 (10):1411-4
22. Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol. 2010;84(3):223-8.
23. Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol. 2009;27(36): 6086-93.
24. Tosi P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Tura S, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004;73(2):98-103.
25. Fakhouri F, Guerraoui H, Presne C, Peltier J, Delarue R, Muret P, et al. Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol. 2004;125(1):96-7.
26. Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008;111(8):4039-47.
27. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366 (19):1759-69.
28. Ssa. gov. The Official Website of the U.S. Social Security Administration [last reviewed or modified, October 10, 2012]. Available from: http://www.ssa.gov/ OACT/STATS/table4c6.html.
29. Gupta N, Liu G, Berg D, Kalebic T, Gomez-Navarro J. Clinical Pharmacokinetics of Intravenous and Oral MLN9708, An Investigational Proteasome Inhibitor: An Analysis of Data From Four Phase 1 Monotherapy Studies. Blood 2010;16 (Abstract 1813).
30. Bianchi G, Ramakrishnan VG, Kimlinger T, Haug J, Rajkumar SV, Kumar S. Investigational Agent MLN2238/MLN9708, a Specific, Orally Available, Small Molecule Proteasome Inhibitor, Shows Promising In Vitro Activity Against Multiple Myeloma Cell Lines. Blood 2010;116(Abstract 3014).
31. Vestal RE. Aging and pharmacology. Cancer. 1997;80(7):1302-10.
32. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med. 1997;13(1):169-83.
33. Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med. 1990;6(2):257-67.
34. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen Ml. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61(3):331-9.
35. Abbott KC, Agodoa LY. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol. 2001;56(3):207-10.
36. Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J. Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Q J Med. 1991;79 (290):517-25.
37. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23(36):9219-26.
38. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33):4976-84.
39. Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul Fibrinolysis. 2007;18 (7):595-8
40. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010;28(1):132-5.
41. Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86(1):23-31.
42. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113-20.
43. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895-903.
44. Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010;11(11):1057-65.
45. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, et al. Efficacy and safety of once weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23): 4745-53.
46. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519-29.